Page last updated: 2024-09-04

glucagon and pasireotide

glucagon has been researched along with pasireotide in 12 studies

Compound Research Comparison

Studies
(glucagon)
Trials
(glucagon)
Recent Studies (post-2010)
(glucagon)
Studies
(pasireotide)
Trials
(pasireotide)
Recent Studies (post-2010) (pasireotide)
26,0391,4983,05442586341

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (25.00)29.6817
2010's7 (58.33)24.3611
2020's2 (16.67)2.80

Authors

AuthorsStudies
Briner, U; Bruns, C; Lewis, I; Meno-Tetang, G; Weckbecker, G1
Culler, MD; Janson, ET; Ludvigsen, E; Oberg, K; Sandler, S; Stridsberg, M; Taylor, JE1
Atkinson, B; Bertherat, J; Biller, BM; Boscaro, M; Darby, CH; Findling, J; Freda, PU; Frohman, LA; Glusman, JE; Grossman, AB; Hu, K; Ludlam, WH; Melmed, S; Petersenn, S; Reincke, M; Snyder, P; Tabarin, A; Wang, Y1
Bouillaud, E; Hu, K; Mann, K; Petersenn, S; Reséndiz, KH; Unger, N; Wang, Y; Weisshaar, B; Zhang, Y1
Brueggen, J; Schmid, HA1
Armstrong, D; Burke, P; Ciaraldi, TP; Henry, RR; Ligueros-Saylan, M; Mudaliar, S1
Breitschaft, A; Darstein, C; Golor, G; Hermosillo Reséndiz, K; Hu, K1
Chen, X; Darstein, C; Hu, K; Hu, P; Jiang, J; Lasher, J; Liu, H; Shen, G1
Florio, T; Gatto, F1
Higashihara, E; Horie, S; Kugita, M; Nagao, S; Nishii, K; Suzuki, A; Yamaguchi, T; Yuzawa, Y1
Arnaldi, G; Barbot, M; Ceccato, F; Lizzul, L; Mondin, A; Plebani, M; Regazzo, D; Scaroni, C; Zaninotto, M; Zilio, M1
Barbot, M; Basso, D; Ceccato, F; Giordano, C; Guarnotta, V; Mondin, A; Regazzo, D; Scaroni, C1

Trials

6 trial(s) available for glucagon and pasireotide

ArticleYear
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
    The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:1

    Topics: Adrenocorticotropic Hormone; Adult; Aged; Blood Glucose; Female; Glucagon; Humans; Hydrocortisone; Insulin; Male; Middle Aged; Oligopeptides; Pituitary ACTH Hypersecretion; Somatostatin

2009
Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
    Journal of clinical pharmacology, 2012, Volume: 52, Issue:7

    Topics: Adult; Blood Glucose; Delayed-Action Preparations; Dose-Response Relationship, Drug; Glucagon; Humans; Infusions, Subcutaneous; Insulin; Male; Somatostatin; Young Adult

2012
Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:8

    Topics: Adolescent; Adult; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucose; Glucose Tolerance Test; Humans; Hyperglycemia; Male; Middle Aged; Somatostatin

2013
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
    Diabetes research and clinical practice, 2014, Volume: 103, Issue:3

    Topics: Adamantane; Adolescent; Adult; Blood Glucose; Cyclohexanes; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Healthy Volunteers; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Prognosis; Pyrrolidines; Somatostatin; Vildagliptin; Young Adult

2014
Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study.
    Clinical therapeutics, 2014, Aug-01, Volume: 36, Issue:8

    Topics: Adult; Asian People; Blood Glucose; China; Cholesterol; Delayed-Action Preparations; Diarrhea; Dizziness; Dose-Response Relationship, Drug; Drug Administration Routes; Glucagon; Healthy Volunteers; Humans; Injections, Intramuscular; Injections, Subcutaneous; Insulin; Male; Nausea; Somatostatin; Triglycerides; Young Adult

2014
Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis.
    Pituitary, 2020, Volume: 23, Issue:5

    Topics: Adult; Blood Glucose; Diabetes Mellitus; Female; Glucagon; Glucagon-Like Peptide 1; Homeostasis; Humans; Insulin; Male; Middle Aged; Pilot Projects; Somatostatin

2020

Other Studies

6 other study(ies) available for glucagon and pasireotide

ArticleYear
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
    European journal of endocrinology, 2002, Volume: 146, Issue:5

    Topics: Animals; Binding, Competitive; Dose-Response Relationship, Drug; Glucagon; Human Growth Hormone; Humans; Insulin Antagonists; Insulin-Like Growth Factor I; Male; Protein Isoforms; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Somatostatin

2002
Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues.
    Regulatory peptides, 2007, Jan-10, Volume: 138, Issue:1

    Topics: Animals; Dose-Response Relationship, Drug; Drug Interactions; Gastrointestinal Agents; Glucagon; Insulin; Insulin Secretion; Islets of Langerhans; Male; Octreotide; Rats; Rats, Sprague-Dawley; Somatostatin

2007
Effects of somatostatin analogs on glucose homeostasis in rats.
    The Journal of endocrinology, 2012, Volume: 212, Issue:1

    Topics: Animals; Blood Glucose; Glucagon; Homeostasis; Hyperglycemia; Insulin; Insulin-Like Growth Factor I; Male; Octreotide; Rats; Rats, Inbred Lew; Receptors, Somatostatin; Somatostatin

2012
Does pasireotide directly modulate skeletal muscle metabolism?
    Endocrine, 2017, Volume: 57, Issue:1

    Topics: Glucagon; Humans; Muscle, Skeletal; Somatostatin

2017
Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease.
    PloS one, 2017, Volume: 12, Issue:5

    Topics: Animals; Blood Glucose; Body Weight; Cyclic AMP; Disease Models, Animal; Drug Interactions; Extracellular Signal-Regulated MAP Kinases; Glucagon; Heart; Humans; Hydrocortisone; Hyperglycemia; Insulin; Insulin-Like Growth Factor I; Ki-67 Antigen; Kidney; Liver; Male; Octreotide; Phosphoproteins; Polycystic Kidney, Autosomal Recessive; Rats; Receptor, IGF Type 1; Ribosomal Protein S6 Kinases; Somatostatin

2017
Incretin Response to Mixed Meal Challenge in Active Cushing's Disease and after Pasireotide Therapy.
    International journal of molecular sciences, 2022, May-06, Volume: 23, Issue:9

    Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Incretins; Insulin; Insulin Resistance; Meals; Pituitary ACTH Hypersecretion; Somatostatin

2022